Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Chilworth, GBR
Southampton Science Park
1 Venture Road, Southampton,
Chilworth, SO16 7NP, GBR

People

Chairman of the Board of Directors
Board of Directors

Funding

TOTAL $6.5M
FUNDING TOTAL $6.5M
Series B, 7/2011
Novo A/S
SV Life Sciences
MVM Life Science Partners
$6.5M

Tags

Vantia Therapeutics

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia’s strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.

Recent Milestones

Videos

Screenshots

Sources

  1. Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds (vantiatherapeutics.com) [edit]
Edit This Page
Last Edited 3/29/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy